title: Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma.
abstract: BACKGROUND
  MicroRNAs are stable and easy to detect in plasma. The plasma levels of microRNAs are often changed in disease conditions, including cancer. This makes circulating microRNAs a novel class of biomarkers for cancer diagnosis. Analyses of online microRNA data base revealed that expression level of three microRNAs, microRNA-24 (miR-24), microRNA-320a (miR-320a), and microRNA-423-5p (miR-423-5p) were down-regulated in colorectal cancer (CRC). However, whether the plasma level of these three microRNAs can serve as biomarkers for CRC diagnosis and prognosis is not determined.
  
  
  METHODS
  Plasma samples from 223 patients with colorectal related diseases (111 cancer carcinoma, 59 adenoma, 24 colorectal polyps and 29 inflammatory bowel disease) and 130 healthy controls were collected and subjected to reverse transcription-quantitative real time PCR (RT-qPCR) analyses for the three microRNAs. In addition, plasma samples from 43 patients were collected before and after surgical treatment for the same RT-qPCR analyses.
  
  
  RESULTS
  The concentrations of plasma miR-24, miR-320a and miR-423-5p were all decreased in patients with CRC and benign lesions (polyps and adenoma) compared with healthy controls, but increased in inflammatory bowel disease (IBD). The sensitivity of miR-24, miR-320a and miR-423-5p for early stage of CRC were 77.78 %, 90.74 %, and 88.89 %, respectively. Moreover, the plasma concentration of the three microRNAs was increased in patients after the surgery who had clinical improvement.
  
  
  CONCLUSIONS
  The plasma levels of miR-24, miR-320a, and miR-423-5p have promising potential to serve as novel biomarkers for CRC detection, especially for early stage of CRC, which are superior to the currently used clinical biomarkers for CRC detection, such as CEA and CA19-9. Further efforts to develop the three microRNAs as biomarkers for early CRC diagnosis and prediction of surgical treatment outcomes are warrant.
authors: Center for Clinical Laboratory, Xiamen University Affiliated Zhongshan Hospital, Xiamen, China. fangzanxi@163.com.
authors: Zanxi
authors: Z
authors: Fang
authors: General Hospital of the Yangtze River Shipping, Wuhan, China. 416695129@qq.com.
authors: Jing
authors: J
authors: Tang
authors: Center for Clinical Laboratory, Xiamen University Affiliated Zhongshan Hospital, Xiamen, China. 627410356@qq.com.
authors: Yongying
authors: Y
authors: Bai
authors: Center for Clinical Laboratory, Xiamen University Affiliated Zhongshan Hospital, Xiamen, China. sophie.lin07@gmail.com.
authors: Huayue
authors: H
authors: Lin
authors: Center for Clinical Laboratory, Xiamen University Affiliated Zhongshan Hospital, Xiamen, China. 939113915@qq.com.
authors: Hanyu
authors: H
authors: You
authors: Center for Clinical Laboratory, Xiamen University Affiliated Zhongshan Hospital, Xiamen, China. 296146742@qq.com.
authors: Hongwei
authors: H
authors: Jin
authors: Center for Clinical Laboratory, Xiamen University Affiliated Zhongshan Hospital, Xiamen, China. doralam07@163.com.
authors: Lingqing
authors: L
authors: Lin
authors: Center for Clinical Laboratory, Xiamen University Affiliated Zhongshan Hospital, Xiamen, China. xmxiamen@aliyun.com.
authors: Pan
authors: P
authors: You
authors: Center for Clinical Laboratory, Xiamen University Affiliated Zhongshan Hospital, Xiamen, China. leeleejuan@qq.com.
authors: Juan
authors: J
authors: Li
authors: Center for Clinical Laboratory, Xiamen University Affiliated Zhongshan Hospital, Xiamen, China. dzdzdz1983@qq.com.
authors: Zhang
authors: Z
authors: Dai
authors: Center for Clinical Laboratory, Xiamen University Affiliated Zhongshan Hospital, Xiamen, China. 178292958@qq.com.
authors: Xianming
authors: X
authors: Liang
authors: Center for Clinical Laboratory, Xiamen University Affiliated Zhongshan Hospital, Xiamen, China. 740033835@qq.com.
authors: Yuanhui
authors: Y
authors: Su
authors: Center for Clinical Laboratory, Xiamen University Affiliated Zhongshan Hospital, Xiamen, China. 541437602@qq.com.
authors: Qing
authors: Q
authors: Hu
authors: Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, TX, USA. fwang@ibt.tmc.edu.
authors: Fen
authors: F
authors: Wang
authors: Center for Clinical Laboratory, Xiamen University Affiliated Zhongshan Hospital, Xiamen, China. zhangzy1121@xmu.edu.cn.|State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, China. zhangzy1121@xmu.edu.cn.
authors: Zhong-Ying
authors: ZY
authors: Zhang
mesh_terms: D000230:Adenocarcinoma / Q000097:blood* / Q000175:diagnosis / Q000556:secondary / Q000601:surgery; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D015179:Colorectal Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000473:pathology / Q000601:surgery; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D012372:ROC Curve; D060888:Real-Time Polymerase Chain Reaction
chemical_list: D014408:Biomarkers, Tumor; C543845:MIRN24 microRNA, human; C572916:MIRN320 microRNA, human; C548900:MIRN423 microRNA, human; D035683:MicroRNAs